Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

BACKGROUND: Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated significant clinical benefit in patients with relapsed/refractory multiple myeloma (RRMM) who had disease refractory to a proteasome inhibitor (PI), an immunomodulator (IMiD), and an anti-CD38 monoclonal antibody base...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Lugui, Xia, Zhongjun, Fu, Chengcheng, Chen, Wenming, Chang, Chunkang, Fang, Baijun, An, Gang, Wei, Yongqiang, Cai, Zhen, Gao, Sujun, Weng, Jianyu, Chen, Lijuan, Jing, Hongmei, Li, Fei, Liu, Zhuogang, Chen, Xiequn, Liu, Jing, Wang, Aihua, Yu, Yang, Xiang, Wenxi, Lynch, Kevin, Yu, Zhinuan, Fu, Weijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981703/
https://www.ncbi.nlm.nih.gov/pubmed/35379237
http://dx.doi.org/10.1186/s12916-022-02305-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981703/
https://www.ncbi.nlm.nih.gov/pubmed/35379237
http://dx.doi.org/10.1186/s12916-022-02305-4

Ejemplares similares